Long-Term Valproate Treatment Increases Brain Neuropeptide Y Expression and Decreases Seizure Expression in a Genetic Rat Model of Absence Epilepsy

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Elms, Johanna ^a,b   Powell, Kim L ^b   van Raay, Leena ^b   Dedeurwaerdere, Stefanie ^c   O'Brien, Terence J ^b   Morris, Margaret J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NEUROPEPTIDE Y; VALPROIC ACID;

ABSENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARCUATE NUCLEUS; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; FOOD INTAKE; GENE EXPRESSION; NERVE CELL NETWORK; NEUROPEPTIDE Y GENE; NONHUMAN; RAT; RAT STRAIN; THALAMUS; UPREGULATION;

ANIMALS; ANTICONVULSANTS; BRAIN; EPILEPSY, ABSENCE; MALE; NEUROPEPTIDE Y; RATS; RATS, WISTAR; SEIZURES; UP-REGULATION; VALPROIC ACID;

EID: 84883643411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073505     Document Type: Article

References (67)

1. Perucca E, (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16: 695-714.
2. Brill J, Lee M, Zhao S, Fernald RD, Huguenard JR, (2006) Chronic valproic acid treatment triggers increased neuropeptide y expression and signaling in rat nucleus reticularis thalami. J Neurosci 26: 6813-6822.
3. Baldino F Jr, Geller HM, (1981) Effect of sodium valproate on hypothalamic neurons in vivo and in vitro. Brain Res 219: 231-237.
4. Chapman AG, Riley K, Evans MC, Meldrum BS, (1982) Acute effects of sodium valproate and gamma-vinyl GABA on regional amino acid metabolism in the rat brain: incorporation of 2-[14C]glucose into amino acids. Neurochem Res 7: 1089-1105.
5. Hariton C, Ciesielski L, Simler S, Valli M, Jadot G, et al. (1984) Distribution of sodium valproate and GABA metabolism in CNS of the rat. Biopharm Drug Dispos 5: 409-414.
6. Martin ED, Pozo MA, (2004) Valproate reduced excitatory postsynaptic currents in hippocampal CA1 pyramidal neurons. Neuropharmacology 46: 555-561.
7. McLean MJ, Macdonald RL, (1986) Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 237: 1001-1011.
8. Thomas A, Mathews G, Ferrendelli J (1996) Mechanisms of action of antiepileptic drugs. In: Wyllie E, editor. The Treatment of Epilepsy: Principles and Practice. 2nd ed. Baltimore: Williams & Wilkins. 700-711.
9. Altrup U, Gerlach G, Reith H, Said MN, Speckmann EJ, (1992) Effects of valproate in a model nervous system (buccal ganglia of Helix pomatia): I. Antiepileptic actions. Epilepsia 33: 743-752.
10. Lucke A, Lehmenkuhler A, Altrup U, Nicholson C, Reith H, et al. (1993) Diffusion analysis of valproate and trans-2-en-valproate in agar and in cerebral cortex of the rat. Brain Res 631: 187-190.
11. Molinari M, Hendry SH, Jones EG, (1987) Distributions of certain neuropeptides in the primate thalamus. Brain Res 426: 270-289.
12. Morris BJ, (1989) Neuronal localisation of neuropeptide Y gene expression in rat brain. J Comp Neurol 290: 358-368.
13. Stroud LM, O'Brien TJ, Jupp B, Wallengren C, Morris MJ, (2005) Neuropeptide Y suppresses absence seizures in a genetic rat model. Brain Res 1033: 151-156.
14. Baraban SC, (2004) Neuropeptide Y and epilepsy: recent progress, prospects and controversies. Neuropeptides 38: 261-265.
15. Redrobe JP, Dumont Y, St-Pierre JA, Quirion R, (1999) Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Res 848: 153-166.
16. Woldbye DP, Nanobashvili A, Sorensen AT, Husum H, Bolwig TG, et al. (2005) Differential suppression of seizures via Y2 and Y5 neuropeptide Y receptors. Neurobiol Dis 20: 760-772.
17. Brill J, Kwakye G, Huguenard JR, (2007) NPY signaling through Y1 receptors modulates thalamic oscillations. Peptides 28: 250-256.
18. Morris MJ, Gannan E, Stroud LM, Beck-Sickinger AG, O'Brien TJ, (2007) Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y2 receptors. Eur J Neurosci 25: 1136-1143.
19. Furtinger S, Pirker S, Czech T, Baumgartner C, Ransmayr G, et al. (2001) Plasticity of Y1 and Y2 receptors and neuropeptide Y fibers in patients with temporal lobe epilepsy. J Neurosci 21: 5804-5812.
20. Bendotti C, Vezzani A, Serafini R, Servadio A, Rivolta R, et al. (1991) Increased preproneuropeptide Y mRNA in the rat hippocampus during the development of hippocampal kindling: comparison with the expression of preprosomatostatin mRNA. Neurosci Lett 132: 175-178.
21. Schwarzer C, Williamson JM, Lothman EW, Vezzani A, Sperk G, (1995) Somatostatin, neuropeptide Y, neurokinin B and cholecystokinin immunoreactivity in two chronic models of temporal lobe epilepsy. Neuroscience 69: 831-845.
22. Gall C, Lauterborn J, Isackson P, White J, (1990) Seizures, neuropeptide regulation, and mRNA expression in the hippocampus. Prog Brain Res 83: 371-390.
23. Pitkanen A, Beal MF, Sirvio J, Swartz KJ, Mannisto PT, et al. (1989) Somatostatin, neuropeptide Y, GABA and cholinergic enzymes in brain of pentylenetetrazol-kindled rats. Neuropeptides 14: 197-207.
24. Sperk G, Marksteiner J, Gruber B, Bellmann R, Mahata M, et al. (1992) Functional changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic seizures in the rat. Neuroscience 50: 831-846.
25. Zachrisson O, Mathe AA, Stenfors C, Lindefors N, (1995) Limbic effects of repeated electroconvulsive stimulation on neuropeptide Y and somatostatin mRNA expression in the rat brain. Brain Res Mol Brain Res 31: 71-85.
26. Bijak M, (1995) Inhibitory effect of neuropeptide y on epileptiform activity in the frontal cortex and hippocampus in vitro. Pol J Pharmacol 47: 461-463.
27. Baraban SC, (2002) Antiepileptic actions of neuropeptide Y in the mouse hippocampus require Y5 receptors. Epilepsia 43Suppl 5: 9-13.
28. Klapstein GJ, Colmers WF, (1997) Neuropeptide Y suppresses epileptiform activity in rat hippocampus in vitro. J Neurophysiol 78: 1651-1661.
29. van Raay L, Jovanovska V, Morris MJ, O'Brien TJ, (2012) Focal administration of neuropeptide Y into the S2 somatosensory cortex maximally suppresses absence seizures in a genetic rat model. Epilepsia 53: 477-484.
30. Woldbye DP, Larsen PJ, Mikkelsen JD, Klemp K, Madsen TM, et al. (1997) Powerful inhibition of kainic acid seizures by neuropeptide Y via Y5-like receptors. Nat Med 3: 761-764.
31. Reibel S, Benmaamar R, Le BT, Larmet Y, Kalra SP, et al. (2003) Neuropeptide Y delays hippocampal kindling in the rat. Hippocampus 13: 557-560.
32. Erickson JC, Clegg KE, Palmiter RD, (1996) Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature. 381: 415-421.
33. Baraban SC, Hollopeter G, Erickson JC, Schwartzkroin PA, Palmiter RD, (1997) Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J Neurosci. 17: 8927-8936.
34. Vezzani A, Michalkiewicz M, Michalkiewicz T, Moneta D, Ravizza T, et al. (2002) Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y. Neuroscience. 110: 237-243.
35. Marescaux C, Vergnes M, Depaulis A (1992) Genetic absence epilepsy in rats from Strasbourg-a review. J Neural Transm Suppl 35: 37-69.
36. Liu L, Zheng T, Morris MJ, Wallengren C, Clarke A, et al. (2006) The mechanism of carbamazepine aggravation of absence seizures. J Pharmacol Exp Ther 319: 790-798.
37. Manning JP, Richards DA, Bowery NG, (2003) Pharmacology of absence epilepsy. Trends Pharmacol Sci 24: 542-549.
38. Dedeurwaerdere S, van Raay L, Morris MJ, Reed RC, Hogan RE, et al. (2011) Fluctuating and constant valproate administration gives equivalent seizure control in rats with genetic and acquired epilepsy. Seizure 20: 72-79.
39. van Raay L, Morris MJ, Reed RC, O'Brien TJ, Dedeurwaerdere S, (2009) A novel system allowing long-term simultaneous video-electroencephalography recording, drug infusion and blood sampling in rats. J Neurosci Methods 179: 184-190.
40. Arens TL, Pollack GM, (2001) Nonstationary disposition of valproic acid during prolonged intravenous infusion: contributions of unbound clearance and protein binding. Biopharm Drug Dispos 22: 243-249.
41. Powell KL, Kyi M, Reid CA, Paradiso L, D'Abaco GM, et al. (2008) Genetic absence epilepsy rats from Strasbourg have increased corticothalamic expression of stargazin. Neurobiol Dis 31: 261-265.
42. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
43. Rowan AJ, Binnie CD, Warfield CA, Meinardi H, Meijer JW, (1979) The delayed effect of sodium valproate on the photoconvulsive response in man. Epilepsia 20: 61-68.
44. Loscher W, (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58: 31-59.
45. Iadarola MJ, Gale K, (1979) Dissociation between drug-induced increases in nerve terminal and non-nerve terminal pools of GABA in vivo. Eur J Pharmacol 59: 125-129.
46. Loscher W, Vetter M, (1985) In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synaptosomal) GABA levels in discrete brain areas of the rat. Correlation to pharmacological activities. Biochem Pharmacol 34: 1747-1756.
47. Loscher W, Siemes H, (1984) Valproic acid increases gamma-aminobutyric acid in CSF of epileptic children. Lancet 2: 225.
48. Loscher W, Siemes H, (1985) Cerebrospinal fluid gamma-aminobutyric acid levels in children with different types of epilepsy: effect of anticonvulsant treatment. Epilepsia 26: 314-319.
49. Loscher W, Schmidt D, (1980) Increase of human plasma GABA by sodium valproate. Epilepsia 21: 611-615.
50. Loscher W, Schmidt D, (1981) Plasma GABA levels in neurological patients under treatment with valproic acid. Life Sci 28: 283-288.
51. Sun QQ, Baraban SC, Prince DA, Huguenard JR, (2003) Target-specific neuropeptide Y-ergic synaptic inhibition and its network consequences within the mammalian thalamus. J Neurosci 23: 9639-9649.
52. Steriade M, (2005) Sleep, epilepsy and thalamic reticular inhibitory neurons. Trends Neurosci 28: 317-324.
53. Sinn DI, Kim SJ, Chu K, Jung KH, Lee ST, et al. (2007) Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis 26: 464-472.
54. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
55. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
56. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, et al. (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 22: 3411-3420.
57. Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, et al. (2007) Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 17: 647-651.
58. Castro LM, Gallant M, Niles LP, (2005) Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J Neurochem 95: 1227-1236.
59. Bredy TW, Wu H, Crego C, Zellhoefer J, Sun YE, et al. (2007) Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem 14: 268-276.
60. Wu X, Chen PS, Dallas S, Wilson B, Block ML, et al. (2008) Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 11: 1123-1134.
61. Reibel S, Larmet Y, Carnahan J, Marescaux C, Depaulis A, (2000) Endogenous control of hippocampal epileptogenesis: a molecular cascade involving brain-derived neurotrophic factor and neuropeptide Y. Epilepsia. 41Suppl 6: S127-133.
62. Reibel S, Vivien-Roels B, Le BT, Larmet Y, Carnahan J, et al. (2000) Overexpression of neuropeptide Y induced by brain-derived neurotrophic factor in the rat hippocampus is long lasting. Eur J Neurosci 12: 595-605.
63. Hamed SA, (2007) Leptin and insulin homeostasis in epilepsy: relation to weight adverse conditions. Epilepsy Res 75: 1-9.
64. Abaci A, Saygi M, Yis U, Demir K, Dirik E, et al. (2009) Metabolic alterations during valproic acid treatment: a prospective study. Pediatr Neurol 41: 435-439.
65. Martin CK, Han H, Anton SD, Greenway FL, Smith SR, (2009) Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial. J Psychopharmacol 23: 814-825.
66. Chao PT, Yang L, Aja S, Moran TH, Bi S, (2011) Knockdown of NPY expression in the dorsomedial hypothalamus promotes development of brown adipocytes and prevents diet-induced obesity. Cell Metab 13: 573-583.
67. Yang L, Scott KA, Hyun J, Tamashiro KL, Tray N, et al. (2009) Role of dorsomedial hypothalamic neuropeptide Y in modulating food intake and energy balance. J Neurosci 29: 179-190.